Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24255

Title: Multipotent adult progenitor cells improve the hematopoietic function in myelodysplasia
Authors: Roobrouck, Valerie D.
Wolfs, Esther
Delforge, Michel
Broekaert, Dorien
Chakraborty, Soumen
Sels, Kathleen
Vanwelden, Thomas
Holvoet, Bryan
Lhoest, Larissa
Khurana, Satish
Pandey, Shubham
Hoornaert, Chloe
Ponsaerts, Peter
Struys, Tom
Boeckx, Nancy
Vandenberghe, Peter
Deroose, Christophe M.
Verfaillie, Catherine M.
Issue Date: 2017
Citation: CYTOTHERAPY, 19(6), p. 744-755
Abstract: Background aims. Myelodysplastic syndromes (MDS) are a group of clonal stem cell disorders affecting the normal hematopoietic differentiation process and leading to abnormal maturation and differentiation of all blood cell lineages. Treatment options are limited, and there is an unmet medical need for effective therapies for patients with severe cytopenias. Methods. We demonstrate that multipotent adult progenitor cells (MAPC) improve the function of hematopoietic progenitors derived from human MDS bone marrow (BM) by significantly increasing the frequency of primitive progenitors as well as the number of myeloid colonies. Results. This effect was more pronounced in a non-contact culture, indicating the importance of soluble factors produced by the MAPC cells. Moreover, the cells did not stimulate the growth of the abnormal MDS clone, as shown by fluorescent in situ hybridization analysis on BM cells from patients with a known genetic abnormality. We also demonstrate that MAPC cells can provide stromal support for patient-derived hematopoietic cells. When MAPC cells were intravenously injected into a mouse model of MDS, they migrated to the site of injury and increased the hematopoietic function in diseased mice. Discussion. The preclinical studies undertaken here indicate an initial proof of concept for the use of MAPC cell therapy in patients with MDS-related severe and symptomatic cytopenias and should pave the way for further investigation in clinical trials.
Notes: [Roobrouck, Valerie D.; Delforge, Michel; Broekaert, Dorien; Sels, Kathleen; Vanwelden, Thomas; Lhoest, Larissa; Khurana, Satish; Pandey, Shubham; Verfaillie, Catherine M.] Katholieke Univ Leuven, Dept Dev & Regenerat, Unit Embryol & Stem Cell Biol, Stem Cell Inst Leuven, O&N4 Box 804,Herestr 49, B-3000 Leuven, Belgium. [Wolfs, Esther; Holvoet, Bryan; Deroose, Christophe M.] Katholieke Univ Leuven, Nucl Med & Mol Imaging & Mol Small Anim Imaging C, Dept Imaging & Pathol, Leuven, Belgium. [Wolfs, Esther; Struys, Tom] Univ Hasselt, Biomed Res Inst, Morphol Res Grp, Diepenbeek, Belgium. [Delforge, Michel; Vandenberghe, Peter] Univ Hosp Leuven, Dept Hematol, Leuven, Belgium. [Chakraborty, Soumen] Inst Life Sci, Dept Gene Funct & Regulat, Bhubaneswar, Orissa, India. [Hoornaert, Chloe] Univ Antwerp, Vaccine & Infect Dis Inst, Lab Expt Hematol, Antwerp, Belgium. [Ponsaerts, Peter; Boeckx, Nancy] Univ Hosp Leuven, Dept Lab Med, Leuven, Belgium. [Boeckx, Nancy] Katholieke Univ Leuven, Dept Oncol, Leuven, Belgium. [Vandenberghe, Peter] Univ Hosp Leuven, Ctr Human Genet, Leuven, Belgium. [Roobrouck, Valerie D.] ReGenesys, Heverlee, Belgium. [Khurana, Satish] Indian Inst Sci Educ & Res, Thiruvananthapuram, Kerala, India.
URI: http://hdl.handle.net/1942/24255
DOI: 10.1016/j.jcyt.2017.03.009
ISI #: 000402027200009
ISSN: 1465-3249
Category: A1
Type: Journal Contribution
Validation: ecoom, 2018
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version1.73 MBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.